Related Experiment Video
Updated: Aug 9, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors
E P Krenning1, J J M Teunissen, R Valkema
1Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. e.p.krenning@erasmusmc.nl
Abstract:
Peptide receptor radionuclide therapy (PRRT) holds great promise for the future regarding the treatment of various cancers. With the use of radiolabelled peptides, which bind with high affinity to their receptors on cancer cells, it is possible to target the cancer efficiently. In gastroenteropancreatic tumors, radiolabelled somatostatin analog therapy has proven to be effective. Dose-limiting organs are the bone marrow and the kidneys. With the currently used dose schemes and kidney protection, PRRT is relatively safe and serious side-effecs are rare. Which radiolabelled somatostatin analog can be regarded as the most effective therapy cannot be concluded from the available literature. Also, the development of therapy strategies with combinations of different radionuclides and or peptides is of interest as these strategies may provide an increase in therapeutic efficacy in the future.
Insights
Peptide receptor radionuclide therapy (PRRT) offers a promising cancer treatment by targeting cancer cells with radiolabeled peptides. While effective for gastroenteropancreatic tumors, further research is needed to determine the most effective somatostatin analog and combination strategies.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmacology
Background:
- Peptide receptor radionuclide therapy (PRRT) utilizes radiolabeled peptides with high affinity for cancer cell receptors to enable targeted cancer treatment.
- Radiolabeled somatostatin analog therapy is an established effective treatment for gastroenteropancreatic tumors.
- The bone marrow and kidneys are identified as dose-limiting organs in PRRT.
Purpose of the Study:
- To review the current state and future potential of Peptide Receptor Radionuclide Therapy (PRRT) in cancer treatment.
- To evaluate the effectiveness of radiolabeled somatostatin analogs in gastroenteropancreatic tumors.
- To explore future therapeutic strategies involving combinations of radionuclides and peptides.
Main Methods:
- Literature review of existing studies on PRRT.
- Analysis of the efficacy and safety of radiolabeled somatostatin analogs.
- Discussion of dose-limiting factors and organ protection strategies.
Main Results:
- PRRT is a promising future treatment for various cancers, with radiolabeled somatostatin analogs effective in gastroenteropancreatic tumors.
- Current PRRT protocols with kidney protection are relatively safe, with rare serious side effects.
- The literature does not definitively conclude which radiolabeled somatostatin analog is most effective.
Conclusions:
- PRRT is a safe and effective targeted cancer therapy, particularly for gastroenteropancreatic tumors.
- Further research is required to identify optimal radiolabeled somatostatin analogs and explore combination therapies to enhance therapeutic efficacy.
